HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.
46 Biggest Movers From Yesterday
Gainers
Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76.
Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide
Midway through trading Tuesday, the Dow traded down 0.49% to 34,698.16 while the NASDAQ fell 0.05% to 15,098.38. The S&P also fell, dropping 0.24% to 4,458.05.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.
Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August
Following the market opening Tuesday, the Dow traded down 0.26% to 34,778.27 while the NASDAQ rose 0.01% to 15,106.84. The S&P also fell, dropping 0.20% to 4,459.89.
What’s Happening With RedHill Biopharma’s Stock On Tuesday?
RedHill Biopharma Ltd (NASDAQ:RDHL) announced preliminary top-line data from Phase 2/3 study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia.…
RedHill Biopharma Says While Preliminary Top-Line Data Of Opaganib Phase 2/3 Study Showed Consistent Trends; The Study Endpoints Did Not Achieve Statistical Significance
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary top-line data from the 475-patient global Phase 2/3
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd’s (NASDAQ:RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients…